Small renal masses in the era of personalized medicine: Tumor heterogeneity, growth kinetics, and risk of metastasis

Alessandro Conti, Matteo Santoni, Valeria Sotte, Luciano Burattini, Marina Scarpelli, Liang Cheng, Antonio Lopez-Beltran, Rodolfo Montironi, Stefano Cascinu, Giovanni Muzzonigro, Lars Lund

Research output: Contribution to journalReview article

8 Citations (Scopus)

Abstract

Small renal masses (SRMs) represent a heterogeneous group showing a variety of clinical and biological behaviors. The best treatment for SRMs has been the focus of much debate over the past decades. Present strategies include surgery (partial or radical nephrectomy), local treatments (radiofrequency and cryoablation), or active surveillance. The choice among these therapeutic options is based on patient clinical features such as age or comorbidities rather than on tumor characteristics. Several studies have recently focused on the molecular behavior of SRMs. They showed that SRMs present histotype and nuclear grading heterogeneity, together with not unvarying growth kinetics and risk of recurrence or metastasis, suggesting that personalized approaches should be designed to optimize the management of these patients. At present, several studies are in course to identify predictive biomarkers to guide the decision-making process in this subpopulation. In this review, we summarized the data on growth kinetics, tumor heterogeneity, and risk of metastasis in patients with SRMs, with focus on the current role of biopsies and imaging in the management of these patients.

Original languageEnglish (US)
Pages (from-to)303-309
Number of pages7
JournalUrologic Oncology: Seminars and Original Investigations
Volume33
Issue number7
DOIs
StatePublished - Jul 1 2015

Fingerprint

Precision Medicine
Neoplasm Metastasis
Kidney
Growth
Neoplasms
Cryosurgery
Nephrectomy
Comorbidity
Decision Making
Therapeutics
Biomarkers
Biopsy
Recurrence

Keywords

  • Active surveillance
  • Diagnosis
  • Nephrectomy
  • Renal biopsy
  • Small renal masses
  • Tumor heterogeneity

ASJC Scopus subject areas

  • Oncology
  • Urology

Cite this

Small renal masses in the era of personalized medicine : Tumor heterogeneity, growth kinetics, and risk of metastasis. / Conti, Alessandro; Santoni, Matteo; Sotte, Valeria; Burattini, Luciano; Scarpelli, Marina; Cheng, Liang; Lopez-Beltran, Antonio; Montironi, Rodolfo; Cascinu, Stefano; Muzzonigro, Giovanni; Lund, Lars.

In: Urologic Oncology: Seminars and Original Investigations, Vol. 33, No. 7, 01.07.2015, p. 303-309.

Research output: Contribution to journalReview article

Conti, A, Santoni, M, Sotte, V, Burattini, L, Scarpelli, M, Cheng, L, Lopez-Beltran, A, Montironi, R, Cascinu, S, Muzzonigro, G & Lund, L 2015, 'Small renal masses in the era of personalized medicine: Tumor heterogeneity, growth kinetics, and risk of metastasis', Urologic Oncology: Seminars and Original Investigations, vol. 33, no. 7, pp. 303-309. https://doi.org/10.1016/j.urolonc.2015.04.001
Conti, Alessandro ; Santoni, Matteo ; Sotte, Valeria ; Burattini, Luciano ; Scarpelli, Marina ; Cheng, Liang ; Lopez-Beltran, Antonio ; Montironi, Rodolfo ; Cascinu, Stefano ; Muzzonigro, Giovanni ; Lund, Lars. / Small renal masses in the era of personalized medicine : Tumor heterogeneity, growth kinetics, and risk of metastasis. In: Urologic Oncology: Seminars and Original Investigations. 2015 ; Vol. 33, No. 7. pp. 303-309.
@article{ff931f5be71349009611aded88d10e67,
title = "Small renal masses in the era of personalized medicine: Tumor heterogeneity, growth kinetics, and risk of metastasis",
abstract = "Small renal masses (SRMs) represent a heterogeneous group showing a variety of clinical and biological behaviors. The best treatment for SRMs has been the focus of much debate over the past decades. Present strategies include surgery (partial or radical nephrectomy), local treatments (radiofrequency and cryoablation), or active surveillance. The choice among these therapeutic options is based on patient clinical features such as age or comorbidities rather than on tumor characteristics. Several studies have recently focused on the molecular behavior of SRMs. They showed that SRMs present histotype and nuclear grading heterogeneity, together with not unvarying growth kinetics and risk of recurrence or metastasis, suggesting that personalized approaches should be designed to optimize the management of these patients. At present, several studies are in course to identify predictive biomarkers to guide the decision-making process in this subpopulation. In this review, we summarized the data on growth kinetics, tumor heterogeneity, and risk of metastasis in patients with SRMs, with focus on the current role of biopsies and imaging in the management of these patients.",
keywords = "Active surveillance, Diagnosis, Nephrectomy, Renal biopsy, Small renal masses, Tumor heterogeneity",
author = "Alessandro Conti and Matteo Santoni and Valeria Sotte and Luciano Burattini and Marina Scarpelli and Liang Cheng and Antonio Lopez-Beltran and Rodolfo Montironi and Stefano Cascinu and Giovanni Muzzonigro and Lars Lund",
year = "2015",
month = "7",
day = "1",
doi = "10.1016/j.urolonc.2015.04.001",
language = "English (US)",
volume = "33",
pages = "303--309",
journal = "Urologic Oncology",
issn = "1078-1439",
publisher = "Elsevier Inc.",
number = "7",

}

TY - JOUR

T1 - Small renal masses in the era of personalized medicine

T2 - Tumor heterogeneity, growth kinetics, and risk of metastasis

AU - Conti, Alessandro

AU - Santoni, Matteo

AU - Sotte, Valeria

AU - Burattini, Luciano

AU - Scarpelli, Marina

AU - Cheng, Liang

AU - Lopez-Beltran, Antonio

AU - Montironi, Rodolfo

AU - Cascinu, Stefano

AU - Muzzonigro, Giovanni

AU - Lund, Lars

PY - 2015/7/1

Y1 - 2015/7/1

N2 - Small renal masses (SRMs) represent a heterogeneous group showing a variety of clinical and biological behaviors. The best treatment for SRMs has been the focus of much debate over the past decades. Present strategies include surgery (partial or radical nephrectomy), local treatments (radiofrequency and cryoablation), or active surveillance. The choice among these therapeutic options is based on patient clinical features such as age or comorbidities rather than on tumor characteristics. Several studies have recently focused on the molecular behavior of SRMs. They showed that SRMs present histotype and nuclear grading heterogeneity, together with not unvarying growth kinetics and risk of recurrence or metastasis, suggesting that personalized approaches should be designed to optimize the management of these patients. At present, several studies are in course to identify predictive biomarkers to guide the decision-making process in this subpopulation. In this review, we summarized the data on growth kinetics, tumor heterogeneity, and risk of metastasis in patients with SRMs, with focus on the current role of biopsies and imaging in the management of these patients.

AB - Small renal masses (SRMs) represent a heterogeneous group showing a variety of clinical and biological behaviors. The best treatment for SRMs has been the focus of much debate over the past decades. Present strategies include surgery (partial or radical nephrectomy), local treatments (radiofrequency and cryoablation), or active surveillance. The choice among these therapeutic options is based on patient clinical features such as age or comorbidities rather than on tumor characteristics. Several studies have recently focused on the molecular behavior of SRMs. They showed that SRMs present histotype and nuclear grading heterogeneity, together with not unvarying growth kinetics and risk of recurrence or metastasis, suggesting that personalized approaches should be designed to optimize the management of these patients. At present, several studies are in course to identify predictive biomarkers to guide the decision-making process in this subpopulation. In this review, we summarized the data on growth kinetics, tumor heterogeneity, and risk of metastasis in patients with SRMs, with focus on the current role of biopsies and imaging in the management of these patients.

KW - Active surveillance

KW - Diagnosis

KW - Nephrectomy

KW - Renal biopsy

KW - Small renal masses

KW - Tumor heterogeneity

UR - http://www.scopus.com/inward/record.url?scp=84930572042&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930572042&partnerID=8YFLogxK

U2 - 10.1016/j.urolonc.2015.04.001

DO - 10.1016/j.urolonc.2015.04.001

M3 - Review article

C2 - 25979651

AN - SCOPUS:84930572042

VL - 33

SP - 303

EP - 309

JO - Urologic Oncology

JF - Urologic Oncology

SN - 1078-1439

IS - 7

ER -